AstraZeneca Signs an Exclusive Option and Research Agreement with Transgene for Oncolytic Immunotherapies

 AstraZeneca Signs an Exclusive Option and Research Agreement with Transgene for Oncolytic Immunotherapies

AstraZeneca Signs an Exclusive Option and Research Agreement with Transgene for Oncolytic Immunotherapies

Shots:

  • Transgene to receive $10M upfront & $3M preclinical milestones, providing its oncolytic virus expertise with Vaccinia Virus (TK-, RR-) double-deleted backbone and will take care of in-vitro pre-clinical development
  • AZ has an option to select 5 oncolytic immunotherapies based on Invir.IO and will be responsible for its in-vivo pre and clinical development with the commercialization of candidates. If AZ exercises its option, Transgene will receive option exercise payment, development & commercial milestones and royalties on sales of each candidate
  • Transgene’s Invir.IO utilizes viral vector technology to design therapies for multifunctional oncolytic viruses. Transgene has various pre and clinical -stage vaccines including TG4010, TG4001 & TG1050, TG6002 for NSCLC, HPV+ head and neck cancers & hepatitis B and solid tumors respectively

Click here to read full press release/ article | Ref: BusinessWire| Image: Veolia

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post